Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.36 |
| ▸ | MAT2A | P31153 | 4/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
| ▸ | FNTA | P49354 | 1/20 | 0.34 |
| ▸ | FNTB | P49356 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23577050 | 0.92 | RORC (0.37) | RORCCYP1A2MAT2APRMT5CYP3A4 | |
| SCHEMBL29909502 | 0.92 | RORC (0.37) | RORCCYP1A2MAT2APRMT5CYP3A4 | |
| SCHEMBL23601032 | 0.91 | RORC (0.40) | RORCFNTAFNTB | |
| SCHEMBL23601393 | 0.91 | MAT2A (0.34) | RORCCYP1A2MAT2APRMT5HSD11B1 | |
| SCHEMBL31229437 | 0.90 | RORC (0.39) | RORCFNTAFNTB | |
| SCHEMBL31169425 | 0.90 | ALDH1A1 (0.39) | RORCCYP1A2MAT2APRMT5FNTA | |
| SCHEMBL23601424 | 0.90 | RORC (0.39) | RORCFNTAFNTB | |
| SCHEMBL23578155 | 0.90 | ALDH1A1 (0.39) | RORCCYP1A2MAT2APRMT5FNTA | |
| SCHEMBL23601235 | 0.90 | FNTA (0.40) | CYP1A2MAT2APRMT5FNTAFNTB | |
| SCHEMBL29909768 | 0.90 | FNTA (0.40) | CYP1A2MAT2APRMT5FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-10-13 | — | — | US | disclosed |
| WO-2021130638-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES, INC. (JP) | 2021-07-01 | — | — | WO | disclosed |
| WO-2021130638-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES, INC. (JP) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | RORC 1542/4885CYP1A2 4595/4885MAT2A 1551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.